tradingkey.logo

Trinity Biotech PLC

TRIB
查看詳細走勢圖
0.800USD
+0.092+13.06%
收盤 02/06, 16:00美東報價延遲15分鐘
15.41M總市值
虧損本益比TTM

Trinity Biotech PLC

0.800
+0.092+13.06%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+13.06%

5天

-1.97%

1月

+5.74%

6月

-10.28%

今年開始到現在

+1.14%

1年

-3.47%

查看詳細走勢圖

TradingKey Trinity Biotech PLC股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Trinity Biotech PLC當前公司基本面數據相對謹慎,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名141/205位。機構持股佔比非常高,中期看,股價處於下降通道。近一個月,市場表現較強,基本面評分較高,但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Trinity Biotech PLC評分

相關信息

行業排名
141 / 205
全市場排名
446 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Trinity Biotech PLC亮點

亮點風險
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
業績增長期
公司處於發展階段,最新年度總收入61.55M美元
估值合理
公司最新PE估值-0.16,處於3年歷史合理位
機構加倉
最新機構持股2.76M股,環比增加9.95%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉171.36K股
活躍度增加
近期活躍度增加,過去20天平均換手率8.62

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Trinity Biotech PLC新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Trinity Biotech PLC簡介

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
公司代碼TRIB
公司Trinity Biotech PLC
CEOGillard (John)
網址https://www.trinitybiotech.com/
KeyAI